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Abstract
Background: The real-time monitoring of polynucleotide amplification is at the core of most molecular assays. This
conventionally relies on fluorescent detection of the amplicon produced, requiring complex and costly hardware, often
restricting it to specialised laboratories.
Principal Findings: Here we report the first real-time, closed-tube luminescent reporter system for nucleic acid amplification
technologies (NAATs) enabling the progress of amplification to be continuously monitored using simple light measuring
equipment. The Bioluminescent Assay in Real-Time (BART) continuously reports through bioluminescent output the
exponential increase of inorganic pyrophosphate (PPi) produced during the isothermal amplification of a specific nucleic
acid target. BART relies on the coupled conversion of inorganic pyrophosphate (PPi) produced stoichiometrically during
nucleic acid synthesis to ATP by the enzyme ATP sulfurylase, and can therefore be coupled to a wide range of isothermal
NAATs. During nucleic acid amplification, enzymatic conversion of PPi released during DNA synthesis into ATP is
continuously monitored through the bioluminescence generated by thermostable firefly luciferase. The assay shows a
unique kinetic signature for nucleic acid amplifications with a readily identifiable light output peak, whose timing is
proportional to the concentration of original target nucleic acid. This allows qualitative and quantitative analysis of specific
targets, and readily differentiates between negative and positive samples. Since quantitation in BART is based on
determination of time-to-peak rather than absolute intensity of light emission, complex or highly sensitive light detectors
are not required.
Conclusions: The combined chemistries of the BART reporter and amplification require only a constant temperature
maintained by a heating block and are shown to be robust in the analysis of clinical samples. Since monitoring the BART
reaction requires only a simple light detector, the iNAAT-BART combination is ideal for molecular diagnostic assays in both
laboratory and low resource settings.
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Introduction
In recent years the molecular amplification of polynucleotides has
become increasingly important in life sciences. Many variants of
these technologies exist, and they increasingly underpin commercial
diagnostic tests as well as a large number of research applications.
Mostdiagnosticapplications relyon detectionofa target nucleicacid
through the process of amplification whose specificity is determined
by the use of oligonucleotide primers complementary to the target
sequence. The full potential of these analytical tools is only realised if
the analysis can detect, report and quantify the amplification
occurring in a closed-tube format inreal-time [1–3]. Such assays can
determine both the presence and concentration of the target in the
original sample in a closed-tube format that minimises the risk of
contaminating other samples with amplified DNA.
The most common real-time detection solutions utilize
fluorescence technologies to report the in-vitro synthesis of
polynucleotides during the polymerase chain reaction (PCR) [4].
Intercalating dyes and fluorescently-labelled oligonucleotides are
the most widely used methods of detection of the ongoing synthesis
of the target amplicon, despite their requirement for relatively
sophisticated optical equipment to excite the fluorophore of choice
and detect the emitted light [5,6]. Unfortunately, the elaborate
nature of such machinery has constrained attempts to produce
robust, low-cost instruments.
Alternative approaches of amplification detection have been
adopted that determine the production of inorganic pyrophos-
phate (PPi), a low-molecular weight by-product of all polynucle-
otide amplification [7–9]. One molecule of PPi is synthesised each
time a nucleotide base is added during the polymerization reaction
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e14155(Figure 1, equation 1). In any given polynucleotide amplification
process, the amount of PPi liberated is therefore proportional to
the amount of polynucleotide synthesized and hence the starting
template concentration; detected PPi can thus be used to quantify
the amount of the original target molecule present in a sample. To
date turbidimetry is the only method available for detecting PPi
continuously in an ongoing amplification reaction. This method
utilises the relative insolubility of the Mg
2+ salt of PPi, which
precipitates at high concentrations and can be quantified by
monitoring the increasing turbidity of the solution. However,
relatively high concentrations of PPi are required and so this
approach is limited to isothermal nucleic acid amplification
technologies (iNAATs) such as loop-mediated amplification
(LAMP) [10,11] that tend to produce large amounts of PPi. There
are several distinct iNAATs available as alternatives to PCR,
which use strand-displacing polymerases instead of heat denatur-
ation to generate single stranded template, and so have the
additional advantage that they run at a constant temperature with
concomitantly reduced equipment and energy requirements [12].
Alternatively, PPi can be converted into ATP and quantitatively
detected using firefly luciferase in an assay known as ELIDA
(Enzymatic Luminometric Detection of Inorganic pyrophosphate
Assay) [13] and in PyrosequencingH [7,9,14,15]. In ELIDA, PPi is
converted into ATP by the enzyme ATP sulfurylase utilising the
substrate adenosine- 59-O-phosphosulfate (APS), and the ATP
generated is simultaneously utilised by firefly luciferase to oxidise
its substrate luciferin with the emission of light (hv) (Figure 1,
equations 2 and 3) [13]. In PyrosequencingH, ELIDA is used to
detect the instantaneous production of PPi as each single
nucleotide base is added step-wise to a polynucleotide chain as it
is synthesized base-by-base on a template molecule. For each
position on the chain, addition of each of the four bases is
attempted until successful addition is determined by PPi
production, measured by light output through ELIDA.
DNA amplification reactions have not, however, been success-
fully monitored in real-time using continuous ELIDA because of a
number of obstacles: i) the relatively high temperatures required
by most iNAATs (.37uC) are incompatible with the poor thermal
stability of firefly luciferase; ii) the inevitable presence of abundant
quantities of dATP required for DNA synthesis during amplifica-
tion leads to high bioluminescent backgrounds, since dATP is an
alternative substrate for firefly luciferase; iii) the possible release of
additional PPi through non-specific priming and non-specific
amplification; and, iv) potential additional contamination with PPi
and ATP from the sample.
The availability of recombinant thermostable firefly luciferases
tolerant to the typical operating temperatures of most iNAATs
(#65uC) suggested the possibility of direct coupling of biolumi-
nescent detection through a continuous ELIDA reaction to an
iNAAT, potentially allowing the continuous determination of
amplification in real-time in a single-tube system [16–18]. Here it
is shown that the use of a thermostable luciferase in a continuously
monitored single-tube system with optimised concentrations of
ATP-producing enzymes allows the quantitative determination of
PPi and hence of the progress of DNA amplification despite the
above-mentioned limitations. Such BART (Bioluminescent Assay
in Real Time) assays are characterised by a unique kinetic
signature, common to several coupled iNAATs tested, that allows
not only the real-time detection, but also the quantitation of the
nucleic acid target, as well as facile determination of negative
samples. The BART signal can be detected using simple
instruments capable of controlling a heating block and of detecting
the significant levels of light produced using photodiodes or a
charge-coupled device (CCD) camera. We confirm the robustness
of the coupled iNAAT- BART assays to potentially inhibitory
components of clinical samples by presenting the results of a pilot
trial evaluating the use of LAMP-BART in Chlamydia trachomatis
(CT) diagnosis from human urine samples.
Results
BART kinetic curves
Among currently available iNAATs, LAMP [19] typically
generates high amplicon yields in reactions normally run at
around 65uC and has been shown to produce sufficient PPi to be
detected either by precipitation as its Mg
2+ salt or through
colorimetry using hydroxy naphthol blue [20]. LAMP has also
been shown to produce quantitative results in a real-time
fluorogenic assay [21], and was therefore selected for initial
investigation of the potential of a coupled bioluminometric assay.
LAMP primers were designed as described in Materials and
Methods complementary to sequences present on the plasmid of
Chlamydia and assayed using a plasmid template synthesized to
contain this sequence, referred to as Chlamydia Artificial plasmid
Template (ChAT). Reactions were conducted in a closed one-tube
format that contained all enzymes and reagents necessary for both
DNA amplification and ELIDA and incubated at 55uC, a
temperature selected as suitable for primer annealing, DNA
synthesis, conversion of PPi to ATP and light emission, as well as
ATP sulfurylase and luciferase stability. Such assays are referred to
as LAMP-BART assays.
To carry out LAMP-BART reactions, hardware was assembled
as described in Materials and Methods, comprising a program-
mable heating block simply housed within a commercially
available chemiluminescence system (essentially a dark box
containing a CCD camera viewing the top of the heating block).
Light measurements from the camera were recorded every minute
for the field of view and analysed by the attached computer.
A profile of light emitted during a positive and a negative ChAT
LAMP-BART reactions was recorded over 60 min (Figure 2). A
light signal from a negative sample that did not contain any
specific template started with a high background and then showed
a continual near-exponential decay throughout the reaction. A
positive sample had a distinct light output profile characterised by
the initially high background decaying for some time in parallel
with the negative sample. Unlike the negative sample, however,
this initial decay was followed by a rapid increase in light intensity
followed by an abrupt decline that diminished below initial
Figure 1. Biochemistry of ELIDA and BART. Schematic biochemical reactions describing nucleic acid amplification (1) coupled with
bioluminescent detection of inorganic pyrophosphate using ELIDA (2) and (3).
doi:10.1371/journal.pone.0014155.g001
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in a graph of light output against time as a sharp peak of light
output (Figure 2A). By the end of the assay, the negative sample
maintained a higher light output compared to the positive sample
(Figure 2B). Positive ChAT LAMP-BART profiles therefore
resulted in highly unusual kinetic curves, very different from the
curves reported when LAMP is monitored using either fluores-
cence or turbidimetry, both of which usually result in sigmoid
curves for positive samples, resembling those associated with real-
time quantitative PCR (qPCR) [11,22].
Effects of ATP, dNTPs, APS and PPi on the light output in
BART
There are two major differences between the sigmoid curves
described above and the BART curve: the first is the high starting
background and the second is the rapid reduction in biolumines-
cence following the increase that occurs during DNA amplifica-
tion. To understand further the origin of these differences, we
considered the effect on light output in BART of the nucleotides
and PPi present in the full reaction.
With respect to nucleotides, the LAMP-BART reaction mixture
initially contains high concentrations of all four dNTPs required for
nucleic acid amplification as well as the ATP sulfurylase substrate,
APS. When a positive sample is amplified in LAMP-BART, it is
anticipated that dNTPs will be depleted as PPi is released, APS is
converted to ATP through reaction with PPi, and ATP is then
hydrolysed by luciferase to yield AMP and PPi. Therefore, in a
positive LAMP-BART assay, a continuous change of concentration
of all four dNTPs, APS, PPi and ATP will occur. All these substances
with the exception of APS are known to affect firefly luciferase
Figure 2. Qualitative and quantitative BART. (A) Typical BART curve (raw experimental data) for a positive sample (red) shows characteristic
time to first inflexion point (tinf) and time to peak (tmax); the curve for a negative sample (black) gradually decays. (B) Images of a positive (+) and a
negative (2) samples at the beginning (a) and at the end (b) of the BART assay. (C) Real-time bioluminescent assay of ChAT DNA dilution series
amplified by LAMP at 55uC for 1 hour (raw experimental data). 5.5610
8 copies – red, 5.5610
7 – orange, 5.5610
6 – yellow, 5.5610
5 – light-green,
5.5610
4 – dark-green, 5.5610
3 – light-blue, 5.5610
2 – dark-blue, 55 – violet, 5.5 – pink, NTC - black. Each curve represents one of three replicates for
5.5610
3–5.5610
8 copies and one of six replicates for 5.5–5.5610
2 measured with or without salmon sperm DNA (100 ng total). (D) Semi-logarithmic
plot of the time to first inflexion point (tinf - blue line) and time to peak (tmax – brown line) versus ChAT DNA copy number in the LAMP-BART
reactions of which representative curves are shown in (C). Bars show standard deviation. Note that all samples are averaged here, both containing
100 ng carrier DNA or without it.
doi:10.1371/journal.pone.0014155.g002
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significant impact on BART light output. ATP and dATP are
luciferase substrates, dCTP, dGTP and dTTP are competitive
inhibitors of luciferase and PPi may have either a stimulating or
inhibitory effect depending on its concentration [24,25]. To
understand better the biochemistry underlying the observed BART
curves, so-called ‘deficient’ formulations of ChAT LAMP-BART
mixture, containing all ingredients except the primers and Bst DNA
polymerase (omitted to prevent any possible specific or non-specific
amplification and primer-dimer formation), were investigated with
different concentrations of dNTPs, ATP, PPi and APS.
The effect of the equimolar mixture of dNTPs (0–1 mM each)
on light output revealed no background light in the absence of
dNTPs and substantial amount of light in the presence of dNTPs
(125 mM and above), with a plateau reached at concentrations
higher than 250 mM (Figure 3A). This is most likely to be due to
the saturation of luciferase with all four dNTPs. Among the four
dNTPs present in the mixture dATP is the most likely luciferase
substrate causing light emission [23]. The level of light signal was
similar to the initial background observed in ChAT LAMP-BART
assays, with a gradual decay of light closely resembling that seen in
the negative ChAT LAMP-BART (Figure 2A) (data not shown).
This decay is typical for all bioluminescent assays utilising firefly
luciferase in the presence of high concentrations of substrates and
is due to the loss of luciferase enzymatic activity through inhibition
by the reaction products, as well as to the gradual thermal
inactivation of the enzyme [26,27]. We therefore consider that the
initial high light output and gradual decay is explained by the
interaction of luciferase with the high concentrations of dNTPs
present in a LAMP-BART reaction.
The effect of ATP was evaluated using ‘deficient’ ChAT LAMP-
BART mixture containing 250 mM each dNTP and varying
Figure 3. Effect of dNTPs, ATP, PPi and APS on light output in BART. Simulation of effects of different ingredients on the light output in
LAMP-BART in a ‘‘deficient mix’’ lacking primers and Bst polymerase but containing all other components as described in each case below. (A) Light
output detected using varying concentrations of an equimolar mixture of four dNTPs. Light output peaks at 500 mM total dNTP concentration. (B)
Light output detected using varying concentrations of ATP in the presence of 250 mM equimolar dNTPs. Light output is higher than in panel (A) and
reaches saturation at 100 mM ATP, showing greater sensitivity to ATP. (C) Inhibitory effect of different concentrations of PPi on the light emission in
the presence of 250 mM dNTPs and 100 mM ATP. (D) Stimulatory effect of increasing concentrations of APS on the light emission in the presence of
250 mM dNTPs and 100 mM PPi. (E) Effect of different concentrations of APS on BART curves in complete LAMP-BART formulation with 10
7 ChAT
target DNA (red – 100 mM, navy – 200 mM, brown – 500 mM, green – 750 mM, blue - 1000 mM). As APS concentration is increased, there is little effect
on peaking time but more PPi is converted to ATP resulting in a lower rate of inhibition of luciferase and a slower ‘‘switch off’’ of light output.
doi:10.1371/journal.pone.0014155.g003
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ATP caused a substantial further increase in the background
followed by steady decay, similar to that described above
(Figure 3A). Addition of 10 mM ATP raised light brightness nearly
4-fold, and 100 mM - 6-fold. Further increase in ATP concentra-
tion was not accompanied by any significant changes in the light
output, suggesting that in these conditions luciferase was saturated
above 100 mM ATP (Figure 3B). The overall higher light output in
this experiment suggests that, even though there was no depletion
of dNTPs, ATP outcompeted dATP as a luciferase substrate and
because of its much higher light-producing efficiency caused an
increase in the total light output [28]. The analogous situation is
likely to explain the ‘‘flash’’ of light in a positive LAMP-BART
amplification, where the increase in light is also facilitated by the
depletion of dNTPs.
To address the rapid decline in light output after the ‘‘flash’’, the
effect of PPi was evaluated using a ‘deficient’ ChAT LAMP-BART
mixture comprising 250 mM each dNTP, 100 mM ATP and
varying concentrations of PPi (0–0.5 mM; Figure 3C). Inclusion of
10 mMP P i had almost no impact on the resulting light output
from dNTPs and ATP, while 50 mMP P i reduced light by 30%,
100 mMP P i by 50%, and 250 mM brought it down to the level of
typical background coming from dNTPs in the absence of ATP;
500 mM reduced it even further (Figure 3C). Hence, in the
presence of high PPi, light output decreased to the level below that
observed with dNTPs alone - a result similar to that observed at
the end of a positive LAMP-BART reaction.
These data are consistent with the explanation that in a positive
LAMP-BART, when amplification occurs, PPi is produced and
converted into ATP, consuming APS. As long as there is sufficient
APS to convert PPi into ATP, the latter is made and provides the
substrate for light production by luciferase. The rapid accumula-
tion of PPi and its conversion to ATP during the exponential phase
of the amplification then leads to a peak in light output (flash). As
APS is exhausted, and if amplification continues, free PPi
accumulates and inhibits luciferase, as shown above [24,25]. This
implies that APS concentration should thus have a significant
effect on the shape of BART curves.
The effect of APS on BART light output was investigated using
both ‘deficient’ and full ChAT LAMP-BART formulations. The
‘deficient’ formulation contained 250 mM each dNTP, 100 mM
PPi and different concentrations of APS (0–250 mM) but neither
Bst polymerase nor primers. The increase in APS concentration in
the presence of a fixed concentration of PPi caused an increase in
light production due to the formation of ATP (Figure 3D). The
overall result was similar to that shown in Figure 3A, when varying
amounts of ATP were introduced directly into the system. The
highest light level achieved was close to that observed from the
direct addition of 100 mM ATP (compare Figure 3B). In the
absence of APS, 100 mMP P i strongly inhibited the background
light produced by 250 mM dNTPs (Figure 3D).
Further investigations were carried out with a full ChAT
LAMP-BART formulation containing Bst polymerase, primers,
250 mM dNTPs, 10
7 copies of ChAT template per reaction and
varying amounts of APS (0–1 mM). In the presence of 100 and
200 mM APS, a rapid and sharp switch-off of the BART flash was
observed. At higher APS concentrations, the light output peaks
became broader and did not decline below background even after
60 minutes (Figure 3E), suggesting continuing conversion of PPi to
ATP. In line with the explanation suggested above, the final
concentration of PPi released through the amplification utilising
250 mM each dNTP could potentially reach 1 mM (assuming full
utilization of all dNTPs). With APS limited to 100–200 mM, only
part of the PPi released would therefore be able to be converted to
ATP, with the further PPi accumulation inhibiting luciferase
activity and further light output [24,25]. The rapid ‘‘switch-off’’
observed as the characteristic feature of a positive LAMP-BART
curve is therefore likely to result from the build-up of PPi, which
cannot be converted into ATP once APS is exhausted.
We conclude that the high initial background in BART is due to
the high content of dATP with a possible slight contribution from
contaminating PPi and ATP. The characteristic ‘‘flash’’ from
positive assays results from rapid ATP production, and the
subsequent switch-off is a consequence of inhibition with PPi,
dependent on APS concentration and ATP sulfurylase enzyme
activity.
Quantitative BART
We next sought to investigate whether the timing of the flash
peak, defined by the signal switch-off unique to BART, provides
potential for quantitative real-time iNAATs. In a defined LAMP-
BART formulation, one may expect that the time required for the
same amount of PPi to be released by virtue of amplification
process to cause a luminescent flash and its switch-off would be
dependent on the amount of nucleic acid target present in the
assay. Therefore, a direct relationship between the time-to-peak
and the starting target concentration might be anticipated.
Quantitative assessment of LAMP-BART was carried out using
the ChAT target (5.5–5.5610
8 target molecules per reaction) in
the presence or absence of 100 ng non-specific salmon sperm
carrier DNA (Figure 2). A positive correlation was observed
between both the time to peak (tmax) and time to first inflexion
point (tinfl) with the template abundance. The apparent tmax values
varied between 12 and 50 minutes and tinfl between 5 and
40 minutes, the timings correlating well with template abundance
(Figure 2C). A logarithmic analysis of tmax and tinfl plotted against
ChAT copy number reveals a linear correlation over seven orders
of magnitude, and down to 55 copies per reaction (Figure 2D).
Below 55 copies, template DNA amplification was still reported,
but a linear relationship with respect to template concentration
was not observed in these conditions. The tmax and tinfl data
achieved for a given copy number were shown to be highly
reproducible, although increased variability was observed when
lower concentrations of template were amplified. Time to first
inflexion point and time to peak are thus directly correlated with
target DNA copy number; this is similar to the correlation
observed in qPCR between cycle time (Ct value) and DNA
template load. Both correlations showed identical gradients with
tinfl having a 6-minute smaller intercept. Time to peak is easy to
define from the raw data output, while calculating tinfl requires
some additional data processing, although tinfl can be used for
faster detection or quantitation of the target present in a sample.
We also note that the presence of 100 ng/assay (5 ng/ml) of
background salmon sperm DNA had no effect on the quantitation
of the target DNA, demonstrating that there is no interference
between measured BART signal and this amount of exogenous
non-specific nucleic acid present in the assay; a key consideration
in measuring unknown samples. It also indicates that reduced
quantitation at low copy number is not due to absolute DNA
concentration.
Correlation of DNA synthesis, PPi release and light output
in LAMP-BART
To determine how much DNA and PPi is produced to generate
a BART light peak, BART output was monitored in parallel with
the independent assessment of DNA synthesis. The real-time
bioluminescent output reported during a LAMP-BART reaction
with two different starting amounts of the ChAT DNA target
Bioluminescent Real-Time Assay
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DNA amplification (monitored using fluorescence and gel-
analysis), at various time intervals during the assay (Figure 4).
Attempted direct end-point measurements of PPi by ELIDA
turned out to be unreliable due to the strong interference from the
varying concentrations of ATP, APS, dATP and other deoxynu-
cleotides.
In end-point fluorescent DNA analysis, amplicon became
detectable at 30 min for the higher target concentration and after
35 min for the lower target concentration and reached 200 mg/ml
at approximately 40 and 50 min, respectively (Figure 4B). The
corresponding calculated concentration of PPi released by that
time in the reaction is approximately 600 mM, a very high level at
which APS would already have been depleted and excess PPi
would therefore be present in the assay. By gel electrophoresis,
LAMP amplicon became visible after 30 min for the higher target
concentration and 40 min for the lower, while saturation of the
fluorescence from ethidium bromide was reached at 45 and
50 min, respectively (Figure 4C and 4D). Direct comparison of
measured amplicon accumulation with the BART signal
(Figure 4A) showed that the detectable appearance of amplicon
coincided with the time to the first inflexion point in the light
output curve. We therefore propose that the increase in light signal
started after a prolonged lag-period required for sufficient
amplicon to be synthesised and PPi released, at which time
nucleic acid amplification became exponential and resulted in the
light flash. With the continuing amplification and further release of
PPi into the system the light levels of the BART assay then
diminished to the lowest point recorded throughout the assay. This
corroborates the mechanism proposed above for the strong
inhibition of firefly luciferase by free PPi, which cannot be
converted into ATP because of APS exhaustion [,24,25]. BART
therefore produces a peak of light in real-time when DNA
amplification goes into exponential phase.
Intensity of light output in BART
Unlike conventional bioluminescent assays, BART measure-
ments are intensity-independent. Conventional luciferase biolumi-
nescent assays measure absolute light intensity and correlate its
brightness with the levels of the analyte of interest [29]. An attempt
to assess and compare the intensity of background light emitted
from a ChAT LAMP-BART assay mix using a plate luminometer
(BMG) failed, because the photomultiplier was overloaded even
when small volumes (down to 5 ml) were measured with the lowest
possible voltage setting and shortest integration time (20 ms).
Though it was impossible accurately to quantify brightness of
BART signals using the plate luminometer, it became clear that
BART signals integrated over 60 s could be several orders of
magnitude higher than those measured in traditional biolumines-
cent assays.
BART quantitation is based on temporal parameters, so it is
not expected that absolute light output levels affect quantitation.
ChAT LAMP-BART amplifications were carried out containing
the same concentration of ChAT DNA (10
6 copies per ml) in
different reaction volumes (0.2-50 ml). The intensity of light
decreased proportionally with the reduction in volume, but the
times to peak remained unchanged, except for a slight increase
with the smallest reaction volume (0.2 ml). Reaction volume did
not affect either observed tmax or peak profile (Figure 5). We
therefore conclude that BART quantitation depends on kinetic
parameters of the coupled reactions affecting the time to light
peak, and not on absolute light output intensity. Taken together
with the high level of light signal, this suggests that assays are
likely to be tolerant of turbid assay samples, and points to the
potential to use low-cost lower sensitivity detection methods for
measuring BART light output such as charge-coupled devices or
photodiodes.
Figure 4. Correlation between bioluminescent output and DNA
production in LAMP-BART. Light output in BART (A) and DNA yield
assayed by end-point fluorescence method (B) and visualised by gel-
analysis (C, D) for two different amounts of ChAT (1 pg/ml – blue,
100 pg/ml - red). Each curve represents one of three replicates. 2%
agarose gel shows LAMP amplicon as a ladder of bands representing
multiple concatamer repeats of the ChAT template using 1 pg/ml (C)
and 100 pg/ml (D) of starting template. The strong band in all lanes
corresponds to luciferin, which is strongly fluorescent under UV
illumination.
doi:10.1371/journal.pone.0014155.g004
Bioluminescent Real-Time Assay
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Unlike the majority of traditional bioluminescent assays, where
highly sensitive detection systems are absolutely essential for
measuring low-level light, BART produces such bright light
outputs that much simpler light detection systems can be
employed. Further, since light is emitted from within the reaction
mixture itself, no external illumination is required as for
fluorescence, and since thermal cycling is not required, substan-
tially simpler hardware can be used to follow BART reactions.
Two instruments were therefore designed: a CCD-based
detector currently suitable for 96- or 384-well formats, where
light reflected by a mirror is detected by a camera from the top of
the assay tube (Figure 6B and C), and very small stand-alone
photodiode-based 8 or 16-well device, suitable for point-of-use
applications or low-resource settings, that reads the emitted light
from the bottom of each tube (Figure 6D). Neither machine has
moving parts and optical design is simple since the samples do not
need to be irradiated. Since quantitation is based upon the
measurements of rates of change of light intensity, the need to
measure accurately absolute light intensity is much less significant
than in conventional bioluminescent assays. BART output can be
monitored directly by imaging emitted light (Figure 6F and Movie
S1) or represented graphically (Figure 6E). Both instruments utilize
algorithms integrated within firmware for data processing to
calculate the time to peak and generate a positive-negative call for
individual samples by evaluating changes in the rate of light
emission. These instruments allow BART to be applied in a wide
range of applications from high-throughput screening to point-of-
care (POC) and other low-throughput applications.
Application of LAMP-BART for detection of Chlamydia
trachomatis in clinical specimens
To assess the application of BART for in vitro diagnostics, an
evaluation of Chlamydia trachomatis (CT) diagnosis in human urine
samples was performed, since there is a demand for high
sensitivity molecular assays capable of diagnosis at POC [30]. To
assess microbial range and selectivity of LAMP-BART for CT
infection in clinical urine samples, DNA purified from 14
different strains of CT was assayed and found to be reliably
detected by the ChAT LAMP-BART assay (Table S1). Analytical
specificity was assessed using DNA purified from 28 pathogenic
bacteria and commensal organisms of the oropharynx and genital
tract (Table S2). No false-positives were detected, demonstrating
the 100%-specificity of the assay.
Bacterial DNA was isolated as described in Materials and
Methods from 105 clinical urine specimens of unknown CT status,
analysed for CT DNA by ChAT LAMP-BART and the results
compared to those from qPCR analysis (Table 1). Samples were
defined as positive if a light peak was observed within 1 hour in
BART and/or had Ct#40 qPCR cycles. 45 urine samples were
diagnosed positive for CT by qPCR, of which LAMP-BART
reported 43 as CT-positive. Importantly, no LAMP-BART false
positives occurred. The two samples identified as CT-positive only
by qPCR had marginal Ct values of 40 cycles. In this comparison,
LAMP-BART showed the same specificity as qPCR and 95.6%
sensitivity (relative to qPCR). Moreover, it took BART less than
60 min to detect CT-positive samples, compared to 120 minutes
with the qPCR used. LAMP-BART thus showed robust behaviour
with these clinical samples and did not appear to be susceptible to
inhibition by potential contaminants present in urine-derived
samples subjected to rapid DNA preparation.
A side-by-side comparison of LAMP-BART with a TaqMan
PCR currently used for clinical diagnosis [31] by the Health
Protection Agency (Cambridge, UK) was carried out using
samples from a Quality Control for Molecular Diagnostics
(QCMD; http://www.qcmd.org) CT panel containing a range
of clinically relevant CT loads. Accurate CT quantification is
considered less significant for the clinical management of an
infection than reliable detection [31] and in both methods the
cryptic plasmid was used as the target for amplification to
enhance sensitivity of detection, there being a multiple but
variable number of copies of cryptic plasmid in CT. Samples were
prepared as described in Materials and Methods, and volumes
used in LAMP-BART were adjusted to those used in TaqMan
PCR to achieve an identical target load in both assays [31]. The
samples used and results are presented in Table 2, and
correlation between tmax values in LAMP-BART and Ct values
in TaqMan PCR is shown in Figure 7A. A linear relationship was
observed across a wide range of target copy number, two different
clinical sampling methods (swabs and urines) and two CT variants
(Swedish isolate and Dutch isolate) (Table 2). The higher level of
Figure 5. BART output in reactions of different volumes. (A)
ChAT LAMP-BART curves recorded at 55uC from reactions of different
volumes containing the same concentration of the target. 50 ml – red,
20 ml – orange, 10 ml – yellow, 5 ml – green, 2 ml – light-blue, 1 ml – dark-
blue, 0.5 ml – purple, 0.2 ml – brown. Each curve represents one of three
replicates. (B) Graph of time to peak against the reaction volume.
doi:10.1371/journal.pone.0014155.g005
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in the results from urine sample 5, which in spite of a five time
higher CT load demonstrated later tmax and Ct value than the
swab sample 4. The linear relationship between tmax in LAMP-
BART and Ct values in TaqMan PCR supports their similar
quantitative ability and the potential use of LAMP-BART for
applications requiring quantification of a target. These results
also mirror the quantitative nature of real-time LAMP using
fluorogenic detection [21].
Detection of CT cryptic plasmid in clinical samples can be
challenged by high levels of additional non-target DNA. Although
a total carrier DNA load of 100 ng (equivalent to 5 ng/ml) did not
affect LAMP-BART quantification (Figure 2C), the effect of
higher levels of DNA on ChAT LAMP-BART was modelled using
salmon sperm carrier DNA. A dilution series of ChAT plasmid
(422.7610
6 copies per reaction) was made in 100 ng/ml salmon
Figure 6. Devices for BART assays and different formats of BART data output. (A) Original laboratory set-up for BART used in the research
presented in this paper. (B–D) Later designs of custom equipment for BART assays. High-throughput CCD-camera based system for laboratory use
available in 96/384-well format. (B) Exploded diagram and picture (C) of the CCD-camera-based device: 1 – light box, 2 – CCD-camera, 3- samples in
standard 0.2 ml PCR tubes or 8-well strips or 96-well plate, 4 – heating block. (D) Portable diode-based device for one or two 8-well strips. (E)
Graphical representation of the data for a dilution series: red – 1 ng, orange – 100 pg, green – 10 pg, blue – 1 pg, black - NTC. (F) Corresponding
images of LAMP-BART reactions taken at 10 (a), 21 (b), 24 (c), 25 (d), 26 (e) and 30 min (f): top row – ChAT DNA dilution series with the decreasing
amount of template 1 ng, 100 pg, 10 pg, 1 pg (left to right); bottom row – no-template control.
doi:10.1371/journal.pone.0014155.g006
Table 1. Results of Chlamydia trachomatis testing by
LAMP-BART and qPCR.
LAMP-BART qPCR
Total number of samples 105 105
CT-positive samples 43 (tmax,60 min) 45 (Ct#40 cycles)
CT-negative samples 62 60 (Ct.40)
Sensitivity, % 95.6 100
Specificity, % 100 100
Assay time 60 min 2.5 hours
Mean tmax or Ct/equivalent
time
33.6 min 35.2 cycles ,1 h 46 min
doi:10.1371/journal.pone.0014155.t001
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the side-by-side comparison with TaqMan PCR (Figure 7B). In
the presence of 1.2 mg of overall total amount of carrier DNA in
the assay ChAT plasmid was detected down to single copies within
50 minutes. Below 70 copies of the target the linearity between the
tmax and target copy number was lost and reproducibility of the
assay was significantly reduced but neither specificity nor
sensitivity of LAMP-BART were affected by the presence of large
amounts of foreign DNA.
Application of RT-LAMP-BART for the detection of
classical swine fever virus
To demonstrate the applicability of BART to the detection of
RNA templates, a model system based on classic swine fever virus
(CSFV) was investigated. Purified RNA from an in vitro
transcribed artificial template was amplified in a closed-tube
one-step format, which included reverse transcription, LAMP
amplification and BART detection reagents. For a wide dilution
series of RNA (10
3–10
10) RT-LAMP-BART resulted in a sequence
of light peaks with tmax showing inverse linear proportionality to
RNA target copy number (Figure 7C and 7D). In the absence of
AMV reverse transcriptase, neither amplification nor light peaks
were detected, indicating the absence of background DNA and
non-specific amplification. BART successfully reported on the
exponential release of PPi through amplification of the cDNA
copies generated from the RNA target in the coupled assay in the
same tube. BART kinetic curves in this coupled RNA-cDNA
amplification had exactly the same profile as in DNA amplification
and the linear correlation between the starting copy number and
tmax was retained. This points to the potential for coupled RT-
LAMP-BART detection and quantification of RNA viral genome
loads for diagnostics in low-resource settings.
Figure 7. DNA and RNA analysis using LAMP-BART. (A) Correlation between tmax values in LAMP-BART (vertical axis) and Ct values in TaqMan
PCR (horizontal axis) obtained in the side-by-side analysis of the samples from the CT QCMD panel. (B) Effect of increased levels of foreign DNA
(1.2 mg salmon sperm DNA/assay) on the sensitivity and speed of ChAT LAMP-BART assay carried out in 26-mla t6 0 uC. (C) Real-time bioluminescent
assay of CSFV RNA fragment dilution series amplified by RT-LAMP at 55uC for 100 min (raw experimental data): 10
10 copies – red, 10
9 – orange, 10
8 –
yellow, 10
7 – green, 10
6 – light-blue, 10
5 – dark-blue, 10
4 – violet, 10
3– pink, NTC - black. Each curve represents one of three replicates. (D) Semi-
logarithmic plot of the time-to-peak versus CSFV RNA copy number in the same RT-LAMP-BART reactions.
doi:10.1371/journal.pone.0014155.g007
Table 2. Summary of the samples used in the comparison of
ChAT LAMP-BART with TaqMan PCR (n/a: not applicable. n/d:
not detectable).
Sample Matrix CT variant
CT load,
cells/ml Ct tmax,m i n
1 Urine n/a 0 n/d n/d
2 Swab n/a 0 n/d n/d
3 Swab Dutch clinical isolate
LGV L2
285 29.8 24.5
4 Swab 5700 24.6 19.2
5 Urine 28500 28.2 22.4
6 Urine Swedish variant unknown 22.4 16.0
doi:10.1371/journal.pone.0014155.t002
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Molecular diagnostic tests provide the ‘‘gold standard’’ in terms
of sensitivity and specificity, and are in principle capable of
detecting single copies of a specific nucleic acid sequence in a
sample through the process of repeated copying by nucleic acid
amplification. There is a rapidly increasing demand for such
molecular diagnostic tests driven by the requirement for sensitive
and accurate determination of contaminating or disease organ-
isms, the presence of adventitious genetic material, or the diagnosis
of genetically determined disease states. In particular, there is a
need for tests providing speed, simplicity and robustness in both
molecular assay and the necessary equipment. Such attributes are
also vital in the low resource settings of the developing world,
where molecular diagnostics have yet to have a widespread
impact.
Currently available molecular diagnostic systems are predom-
inantly based on qPCR, with the amplification reported by the
increasing fluorescent signal from an intercalating dye, dye-
labelled primer or labelled probe [1–4]. However, qPCR imposes
strict requirements on the assay equipment, because of the
combined need for temperature cycling, and wavelength-specific
fluorescent excitation and emission measurement. These in turn
pose limitations through the power consumption and optical
arrangements required and have therefore restricted the produc-
tion of low-cost, simple and robust instruments.
A solution to both the temperature cycling and fluorescence
excitation and detection problems is provided by combining
alternative amplification methods based on isothermal amplifica-
tion using strand-displacing polymerases with the bioluminescent
reporting of amplification. We show here that a real-time
bioluminescent assay, BART can be produced by the simultaneous
amplification of a nucleic acid target, conversion of the
pyrophosphate produced to ATP, and its determination with a
thermostable firefly luciferase. Importantly, this assay can be
carried out as a simultaneous combined assay in a single closed
tube without further additions, greatly reducing the risk of
amplicon contamination of further samples. We further show that
such assays can be effectively used on patient-derived samples, that
straightforward and cost-effective instruments can be devised for
the performance of BART assays, and that they are applicable to
RNA targets through coupled reverse transcription.
The BART reporter is unique and clearly distinguishable from
any other system used for real-time monitoring of nucleic acid
amplification. The characteristic BART bioluminescent signature
does not have the sigmoidal shape typical of fluorescent and
turbidimetry measurements. It initiates with a high but rapidly
declining background signal, followed in the case of a positive
sample by a brighter flash and a rapid decline in light intensity.
BART curves of this shape were observed not only when
amplifying the ChAT template using LAMP, but also using other
iNAATs and a range of DNA or viral RNA targets, the latter
involving a simultaneous reverse-transcription step with LAMP.
The BART light output was found to have the same characteristic
shape independent of template, reaction conditions or iNAAT
involved, reflecting the exponential production of the amplicon
and release of PPi. BART assays therefore depend on the coupled
amplification technology used, as BART simply reports on any
resultant exponential release of PPi. We conclude that the
dynamics of light output are characteristic of the coupled reactions
involved in BART and not any specific amplification.
The high bioluminescent background observed in BART is an
inevitable consequence of the reagents required for amplification,
but is not problematic for the assay because the BART
bioluminescent output reflects the rapid dynamic changes in the
relative levels of PPi and ATP. The range of these changes is over
two orders of magnitude (0.01–1 mM) and is unique among
existing bioluminescent methods. The detectable light output at
the beginning of the assay serves as an indicator of BART-reagent
viability, and the residual background signal clearly signals non-
amplified samples where target nucleic acid is not present. The
ability of BART to cope with the presence of dATP, ATP and PPi
emphasises its distinction from previous manifestations of ELIDA
[7–9,13], which are intolerant to their presence as contaminants
and strongly depend on minimising the non-specific background.
This tolerance of BART to high background light levels eliminates
the need for alternative but less satisfactory solutions such as the
use of apyrase to remove ATP, or of d-a-S-ATP, an analogue of
dATP which is not a substrate for firefly luciferase and hence does
not generate a bioluminescent signal, but which can be
incorporated into a nucleic acid, albeit at a much slower rate [33].
Because of the continuous monitoring of light and the
measurement of the rate of change of light intensity rather than
absolute light levels, BART is quintessentially different from
conventional bioluminescent methods based on firefly luciferase in
its tolerance to high bioluminescent background, brightness of its
light output and quantitation relying on peak timing rather than
absolute light intensities. This also provides tolerance to
contaminating ATP or PPi from the sample, since rate of change
not absolute levels are determined.
Dynamic changes in light intensity are therefore a key feature of
BART, allowing analysis to be based on the rate of change of light
production rather than absolute light intensity values. A theoretical
drawback of BART might be the possible difficulty in distinguish-
ing different sources of PPi production, for example from non-
specific processes. However, specific amplification can be
differentiated from non-specific by analysing kinetic rates of light
output. In non-specific amplification, PPi release is usually slow,
non-exponential and not followed by a rapid switch off due to the
slower rate. Hence when a wide peak is observed, either with or
without a subsequent reduction of the light signal below the
background level, it most likely originates from non-specific
amplification. We note that the occurrence and frequency of any
non-specific amplification is an inherent property of the
amplification technology used rather than the BART reporter
system, as BART has been found to have no effect on the
specificity of amplification. The LAMP-BART combination is
particularly favourable as LAMP relies on six primers and eight
recognition sites as opposed to the two amplification primers and
third detection primer if used in PCR and thereby facilitates a
higher specificity of amplification. Nevertheless, assays must be
designed and validated to ensure that off-target exponential
amplification does not occur, since BART will report on all
exponential amplification occurring within the assay, and does not
offer the potential for melt-curve analysis or primer binding
detection that can be used with qPCR.
We further show that the BART reporter system allows
quantitation of the target nucleic acid initially present. It is the
only known quantifiable real-time reporter of amplification
characterized by time-to-peak rather than by absolute signal
output, suggesting a potential greater tolerance of inhibitors or
turbid samples resulting from rapid sample preparation methods.
The reported profile yields more information than either
fluorescence or turbidimetry, both of which generate sigmoid
curves. In BART it is possible to derive values for quantitation
from either time to the first inflexion point (tinfl) of the curve or
time to its maximal light output (tmax). Accurate analysis of time to
peak can be performed with minimal data processing, and it is easy
Bioluminescent Real-Time Assay
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both parameters can be used for quantitation of the target in a way
similar to using Ct values in conventional qPCR, time to the first
inflexion may be of particular value in applications where time to
result is of the essence.
Detection and measurement of BART signals does not require
sophisticated optics or light detection methods. The high tolerance
to absolute light intensity means that hardware specifications can
tolerate wide variances, enabling low-cost manufacture. The high
tolerance to absolute light intensity also widens the range of
possible assay volumes. The potential for reducing BART reaction
volume without alterations to hardware is practically attractive.
BART assays on both instruments described here can be
performed in total volumes as low as 2.5 or even 1 ml. The
volume reduction results in a lower light output but has no effect
on rates of change. Reduction in reaction volume offers savings in
reagent costs without sacrificing test parameters and confers
potential for miniaturisation. BART cannot be multiplexed
conventionally, since if multiple targets of unknown initial
concentration are simultaneously amplified, BART will report
on the total PPi released from all targets and will be unable to
distinguish between them. However the ease and low cost of
BART reactions coupled with the flexibility of camera-based
equipment to follow large sample numbers through simple image
analysis allows multiple reactions to be run simultaneously.
A further advantage that follows from BART’s measurements of
the kinetics of light output is its robustness to sample contaminants.
This includes compounds that could affect luciferase activity, but
also the ability of BART to tolerate addition of turbid samples or
solid particulates. If the latter causes light absorbance or scattering
and reduces absolute light intensity without effecting changes of
reaction rates, both qualitative and quantitative analysis of the data
are still feasible. This feature is important for molecular diagnostic
applications where sample preparation contributes substantially to
the cost and time of the whole assay and tolerance to magnetic
beads or any other solid particles or pigments represents a
significant advantage. Indeed the small trial performed on a panel
of human urine specimens demonstrated that LAMP-BART
showed robust behaviour, reliably detected CT DNA and was not
susceptible to inhibition by potential contaminants present in urine-
derived samples subjected to rapid DNA preparation.
Conclusions
BART- the bioluminescentmonitoring usingcoupled conversion
of inorganic pyrophosphate to ATP and the simultaneous
monitoring of ATP levels using thermostable firefly luciferase -
provides an effective system for reporting isothermal nucleic acid
amplification in real time. It measures light generated in the process
of amplification in a closed tube format and offers the potential for
both quantitative and qualitative assays that are simple, fast, robust
and low-cost in terms of equipment requirements. BART addresses
requirements of molecular diagnostics and is well suited for use in a
range of settings and in a wide variety of formats.
Methods
Materials and reagents
Unless otherwise noted, chemicals were purchased from Sigma
with the exception of luciferin potassium salt (LH2; Europa
Biotech, Ely, UK), UltraGlow firefly luciferase (UGrLuc; Pro-
mega, WI, USA), adenosine-59-O-phosphosulphate (APS; Biolog
Life Science Institute, Bremen, Germany), Bst DNA polymerase
large fragment (Bst) and ThermoPol buffer (New England Biolabs,
MA, USA), QuantiTech SYBR Green PCR kit (Qiagen, Hilden,
Germany), cloned AMV reverse transcriptase and PicoGreen
dsDNA Quantitation kit (Invitrogen, CA, USA). Oligonucleotides
were synthesized at the Department of Biochemistry, University of
Cambridge (UK).
Template selection and primer design
A 224-base pair (bp) Chlamydia trachomatis (CT) artificial template
(ChAT) was constructed using the Expand High Fidelity PCR
System (Roche Applied Science, Indianopolis, IN, USA) from two
overlapping oligonucleotides with a 25 bp overlap that reproduces
a unique sequence from CT cryptic plasmid ORF8 (Genbank
accession NC_001372; positions 1088–1311) which is identical in
all CT strains harbouring this gene. A 224-base pair fragment was
cloned into pCR2.1 Topo vector (Invitrogen). Sequences of six
oligonucleotides including two Lamp, two loop and two displacing
primers designed against the same sequence as described in [19]
are shown in Table 3.
LAMP-BART assay
Optimised LAMP-BART reagent contained 0.2 mM of each
displacing primer, 0.4 mM each loop primer, 0.8 mM each LAMP
primer, 200 mM each dNTP, 0.16 U/ml Bst DNA polymerase
large fragment, 100 mg/ml LH2, 100 uM APS, 0.5 U/ml ATP
sulfurylase, 5.6–6.2 mg/ml UGrLuc, 60 mM KCl, 0.4 mg/ml
polyvinylpyrrolidone and 10 mM DTT in 16ThermoPol buffer
(final concentrations in assay tube are given). BART reactions
were run at 55uCi n2 0ml total volume containing 15 ml reagent
mix with 5 ml added template solution unless otherwise stated.
Template was pre-denatured (5 min, 95uC). Reaction mixtures
were covered with mineral oil to prevent evaporation. Each
sample was run in triplicate.
Hardware
The LAMP-BART assay was carried out on an assembled
instrument comprising a PC-controlled TRobot thermocycler
(Biometra, Go ¨ttingen, Germany) placed beneath a CCD camera
within a ‘Chemi Genius Bio Imaging System’ (Syngene, Cam-
bridge, UK; Figure 6A). This allowed the light emissions to be
quantified at any position on the 96-well heating block and
measure simultaneously from either a 0.2 ml PCR tubes, 8-well
strips or a 96-well PCR plate. Light was integrated over a
60 second intervals using custom software ‘ReactIVD’ (Synoptics,
Cambridge, UK) and data saved as images, graphs and Excel
spreadsheets.
LAMP-BART kinetics
1 pg and 100 pg of the ChAT plasmid were run in 50 ml
LAMP-BART reactions at 55uC. Full BART kinetic curves from
each ChAT concentration were recorded over 60 min. One
Table 3. Sequences of six ChAT primers.
Name Sequence
LampB gaccgaaggtactaaacaagtttttttgtttaggaatcttgttaagg
LampF cgcatctaggattagattagattttattggtctattgtccttgg
LoopB cgagcagcaagctatatt
LoopF aaactcttgcagattcata
DisplB tattccttgagtcatcc
DisplF gatcatatcgaggatctt
doi:10.1371/journal.pone.0014155.t003
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ice at 0, 10, 20, 25, 30, 35, 40, 45, 50, 55 and 60 min. DNA
concentration in collected samples was determined using Pico-
GreenH dsDNA Quantitation Kit (Qiagen, Hilden, Germany)
following the manufacturer’s protocol using a Cary Eclipse
fluorimeter (Varian, CA, USA), or by gel electrophoresis run on
2% agarose gels with ethidium bromide visualisation.
LAMP-BART detection of Chalmydia trachomatis in
clinical specimens
Analytical specificity and microbial range of LAMP-BART
were tested on DNA from 14 different strains of CT (Table S1) and
from a panel of 28 other pathogenic bacteria and commensals
from the oropharynx and genital tract (Table S2). LAMP-BART
reactions were run with 2–20 pg DNA. Bacterial DNA was
isolated from 0.5 ml urine specimens obtained upon approval of
the NHS Research Ethics Committee from 105 patients presenting
to the Genitourinary clinic at Addenbrooke’s Hospital (Cam-
bridge, UK) using ChargeSwitch gDNA Mini Bacteria Kit
(Invitrogen, CA, USA) following the manufacturer’s protocol.
The data were analyzed anonymously and did not require patient
consent. All urine specimens were either stored at +4uC for #5
days or frozen within 5 days of collection and stored at 220uC.
Each sample was analysed in duplicate by BART and in-house
qPCR in parallel with a ChAT dilution series used for calibration.
qPCR was run in 10 ml reactions containing 16 QuantiTech
SYBR Green PCR reagent, 0.4 mM forward and reverse primers
(TTCCTTGAGTCATCCTGTTTAGG and TTGTCCTTGG-
ATATGAATCTGC, respectively) and 2.5 ml of the sample.
qPCR was run on Rotor Gene 3000 (Corbett Research, Australia)
using the following profile: 10 min at 94uC, then 50 cycles of
30 s at 94uC, 30 s at 56uC, 45 s at 72uC, then 15 s at 72uC
and a melt step.
LAMP-BART comparison with TaqMan PCR
CT QCMD 2010 panel (Qnostics, UK) was used in the side-by-
side comparison of ChAT LAMP-BART and TaqMan PCR.
Samples were resuspended in 200 ml of molecular grade water
(except for sample 5 resuspended in 1 ml). 200 ml of each sample
were extracted using Qiagen DX Reagent Pack on Corbett
Robotics Extractor connected to a vacuum pump. Extracted DNA
was eluted in 100 ml of molecular grade water. Fully evaluated
TaqMan PCR used for CT routine screening of urine and swab
clinical specimens at Health Protection Agency laboratories in
Cambridge, UK, was carried out by introducing 12 ml of extracted
samples to 14 ml of the reagent [31]. qPCR was run on Rotor
Gene 6000 (Qiagen, Germany). To make target loads identical
between the amplification assays the volumes of sample and
reagent used in LAMP-BART were adjusted to 12 and 14 ml,
respectively, with the final concentrations of all ingredients
remaining as described above. LAMP-BART was run at 60uC
for 90 min.
RT-LAMP-BART of purified classic swine fever RNA
A pGEM construct containing 163-base pair (bp) DNA
fragment complementary to the classic swine fever viral RNA
(CSFV) sequence was a kind gift from Friedrich-Loeffler-Institut
(Germany). Sequences of the CSFV target and five oligonucleo-
tides including two Lamp, two loop and one displacing primer
designed against the sequence as described in [19] are shown in
Table 4.
RNA was in-vitro transcribed from the pGEM construct
using AmpliScribe
TM T7 High Yield Transcription Kit (EPICEN-
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facturer’s recommendations. To achieve full removal of DNA
the mixture was treated twice with RNAse free DNAse. Quality
and concentration of RNA preparations was assessed spectropho-
tometrically using a Nanodrop spectrophotometer (Thermo
Scientific).
RT-LAMP-BART reagent contained 0.4 mM of displacing
primer F, 0.8 mM each loop primer, 1.6 mM each LAMP primer,
300 mM each dNTP, 0.16 U/ml Bst DNA polymerase large
fragment, 1.5 U/ml cloned AMV reverse transcriptase, 100 mg/ml
LH2, 100 uM APS, 0.5 U/ml ATP sulfurylase, 5.6–6.2 mg/ml
UGrLuc, 50 mM KCl, 0.4 mg/ml polyvinylpyrrolidone and
10 mM DTT in 16 ThermoPol buffer (final concentrations in
assay tube are given). BART reactions were run at 55uCi n2 0ml
total volume containing 15 ml reagent mix with 5 ml added
template solution. Reaction mixtures were covered with mineral
oil to prevent evaporation. Each sample was run in triplicate.
Supporting Information
Table S1 Chlamydia strains tested for inclusivity.
Found at: doi:10.1371/journal.pone.0014155.s001 (0.03 MB
DOC)
Table S2 Pathogenic bacteria and commensal organisms of the
oropharynx and genital tract tested for cross-reactivity.
Found at: doi:10.1371/journal.pone.0014155.s002 (0.04 MB
DOC)
Movie S1 LAMP-BART of a ChAT dilution series: red - 1 ng,
orange - 100 pg, green - 10 pg, blue - 1 pg, black - no-template
control. Top row - ChAT DNA dilution series with decreasing
amount of template (left to right); bottom row - no-template
control.
Found at: doi:10.1371/journal.pone.0014155.s003 (0.85 MB
MOV)
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